1. Homepage
  2. Equities
  3. Poland
  4. Warsaw Stock Exchange
  5. Mabion S.A.
  6. News
  7. Summary
    MAB   PLMBION00016

MABION S.A.

(MAB)
  Report
Delayed Warsaw Stock Exchange  -  05/17 11:55:43 am EDT
27.98 PLN   +1.75%
04/21Mabion S.A. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
2021Mabion S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
CI
2021MABION S.A.(WSE : MAB) added to S&P Global BMI Index
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Mabion S.A. Reports Earnings Results for the Third Quarter Ended September 30, 2020

11/23/2020 | 11:25am EDT

Mabion S.A. Announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced operating loss was PLN 10.186 million compared to PLN 14.404 million a year ago. Net loss was PLN 9.119 million compared to PLN 16.733 million a year ago. For the nine months, operating loss was PLN 39.217 million compared to PLN 46.656 million a year ago. Net loss was PLN 39.948 million compared to PLN 48.429 million a year ago.


ę S&P Capital IQ 2020
All news about MABION S.A.
04/21Mabion S.A. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
2021Mabion S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended Septem..
CI
2021MABION S.A.(WSE : MAB) added to S&P Global BMI Index
CI
2021Mabion S.A. Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
2021Big pharma and private equity seek healthy returns in Europe's east
RE
2021MABION Announces Executive Changes
CI
2021Mabion S.A. Reports Earnings Results for the Full Year Ended December 31, 2020
CI
2021Mabion S.A. Auditor Raises 'Going Concern' Doubt
CI
2021Polish Biotech Mabion Enters Deal To Manufacture Novavax COVID-19 Jab
MT
2021Mabion Biotech Signs Deal with Novavax on Covid-19 Vaccine Technology Transfer
CI
More news
Financials
Sales 2021 8,00 M 1,81 M 1,81 M
Net income 2021 -59,0 M -13,4 M -13,4 M
Net Debt 2021 20,8 M 4,71 M 4,71 M
P/E ratio 2021 -7,62x
Yield 2021 -
Capitalization 452 M 102 M 102 M
EV / Sales 2021 59,1x
EV / Sales 2022 1,65x
Nbr of Employees 213
Free-Float 63,7%
Chart MABION S.A.
Duration : Period :
Mabion S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MABION S.A.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Last Close Price 27,98 PLN
Average target price 68,50 PLN
Spread / Average Target 145%
EPS Revisions
Managers and Directors
Krzysztof Kaczmarczyk President-Management Board & CEO
Grzegorz Mariusz Grabowicz Finance Director
Robert Leszek Konski Independent Member-Supervisory Board
Slawomir Jaros Chief Operating & Scientific Officer
David John James Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
MABION S.A.-54.99%99
GILEAD SCIENCES, INC.-12.99%78 068
REGENERON PHARMACEUTICALS, INC.5.71%70 575
VERTEX PHARMACEUTICALS19.24%65 005
WUXI APPTEC CO., LTD.-16.20%42 275
BIONTECH SE-41.35%36 745